MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of its common stock. In addition, TELA expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities to be sold in the proposed offering at the public offering price for the common stock, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants are being offered by TELA. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering.
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZYXI - April 20, 2025
- Writer/painter-turned cultural heritage preserver behind Spring Festival’s UNESCO heritage status success - April 20, 2025
- Boston Hemp Launches New Line of Premium THCa Concentrates - April 20, 2025
